Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2010-07-21
2011-12-13
Weddington, Kevin E (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S396000, C514S613000
Reexamination Certificate
active
08076335
ABSTRACT:
In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
REFERENCES:
patent: 4455256 (1984-06-01), Urist
patent: 4675183 (1987-06-01), Kato et al.
patent: 5227373 (1993-07-01), Alexander et al.
patent: 5260291 (1993-11-01), Lunt et al.
patent: 5268368 (1993-12-01), Palepu
patent: 5731304 (1998-03-01), Baer et al.
patent: 6251886 (2001-06-01), Friedman
patent: 6803365 (2004-10-01), Niewohner et al.
patent: 2004/0043001 (2004-03-01), Ugwu et al.
patent: 2006/0100188 (2006-05-01), Zong et al.
patent: 0653210 (1995-05-01), None
patent: 63 313721 (1988-12-01), None
patent: 1 479 049 (1989-05-01), None
Sampson, J.H., “Treatment of Neoplastic Meningitis with Intrathecal Temozolomide”, Clinical Cancer Research, vol. 5, pp. 1183-1188 (1999).
Baker, S.D., “Absorption, Metabolism, and Excretion of14C-Temozolomide following oral Administration to Patients with Advanced Cancer”, Clinical Cancer Research, vol. 5, pp. 309-317 (1999).
Further submission in opposition proceedings against EP1478339 (papers dated Jun. 17, 2010, Jun. 28, 2010, Jul. 29, 2010 and Nov. 12, 2010).
Marzolini, C., et al., “Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous, and hepatic intra-arterial administration” Cancer Chemotherapy and Pharmacology, vol. 42, No. 6, pp. 433-440, (1998).
Slack, AJ., et al., “Phase I clinical pharmacokinetics of temozolomide (CCRG81045, NSC362856)” Proceedings of the American Association for Cancer Research, vol. 30, p. 250, Abstract 993 (1989).
PCT International Search Report dated Jun. 20, 2003 for corresponding PCT Application No. PCT/US03/05018.
Submission in opposition proceedings against EP 1478339 (papers dated Jun. 17, 2010 and Jun. 28, 2010).
Ihnat Peter M.
Radhakrishnan Vinay
Ugwu Sydney
Witchey-Lakshmanan Lenore C.
Schering Corp.
Weddington Kevin E
LandOfFree
Processes of making pharmaceutical formulations of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processes of making pharmaceutical formulations of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes of making pharmaceutical formulations of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299555